FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1)
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 597.2-598
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 348.2-349
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 350.2-351
◽
2015 ◽
Vol 173
(6)
◽
pp. 1387-1399
◽
2016 ◽
Vol 74
(5)
◽
pp. AB248
2014 ◽
Vol 70
(5)
◽
pp. AB174
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 863.2-864
◽